Suggested Remit: To appraise the clinical and cost effectiveness of lorlatinib within its marketing authorisation for treating ALK-positive advanced non-small-cell lung cancer.
Status In progress
Process STA 2018
ID number 1338

Project Team

Project lead Kate Moore

Email enquiries

Evidence Review Group / Assessment Group Centre for Reviews and Dissemination and Centre for Health Economics – York


Companies sponsors Pfizer (lorlatinib)
Others Department of Health and Social Care
  NHS England
  NHS Havering CCG
  NHS West Suffolk CCG
  Welsh Government
Patient carer groups ALK Positive UK
  Black Health Agency
  British Lung Foundation
  Cancer Black Care
  Cancer Equality
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Muslim Council of Britain
  Roy Castle Lung Cancer Foundation
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
  UK Lung Cancer Coalition
Professional groups Association of Cancer Physicians
  Association of Respiratory Nurse Specialists
  British Geriatrics Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  British Thoracic Oncology Group
  British Thoracic Society
  Cancer Research UK
  National Lung Cancer Forum for Nurses
  Primary Care Respiratory Society UK
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Health Forum
  UK Oncology Nursing Society


Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord Healthcare (carboplatin, cisplatin)
  Allergan (docetaxel)
  Boehringer Ingelheim (nintedanib)
  Dr. Reddy’s Laboratories (docetaxel, pemetrexed)
  Eli Lilly (pemetrexed)
  Hospira UK (carboplatin, cisplatin, docetaxel)
  Medac GmbH (docetaxel)
  Merck Sharp & Dohme (pembrolizumab)
  Roche Products (atezolizumab, bevacizumab)
  Sandoz (cisplatin)
  Sanofi (docetaxel)
  Seacross (docetaxel, pemetrexed)
General commentators All Wales Therapeutic and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Lung Cancer Group
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research


Key events during the development of the guidance:

Date Update
02 May 2019 Invitation to participate
19 December 2018 Following the referral of lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer to NICE by the Department for Health and Social Care. Following on from advice received from the company, the timelines are currently to be confirmed. Therefore, we are suspending this appraisal. We will provide a further update and timelines in due course.
25 October 2018 The company who produces lorlatinib, Pfizer, has requested more time to allow additional data to be included in the submission. As a consequence, the first committee meeting discussion has been moved to 16 April 2019.
06 September 2018 Invitation to participate
28 June 2018 - 26 July 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
05 December 2017 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance